UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

(Mark  One)

[X]  QUARTERLY  REPORT  PURSUANT  TO  SECTION  13  OR  15(d)  OF  THE
     SECURITIES  EXCHANGE  ACT  OF  1934

     For  the  quarterly  period  ended  December  31,  2005

                                       OR

[ ]  TRANSITION  REPORT  PURUSANT  TO  SECTION  13  OR  15(d)  OF  THE
     SECURITIES  EXCHANGE  ACT  OF  1934

                        Commission file number 33-19598-D

                                    VYTA CORP
                                    ---------
        (Exact name of small business issuer as specified in its charter)

                Nevada                                  84-0992908
                ------                                  ----------
    (State or other jurisdiction of                  (I.R.S. employer
     incorporation or organization)               identification  number)

                           370 17th Street, Suite 3640
                             Denver, Colorado 80202

                    (Address of principal executive offices)

         Issuer's telephone number, including area code:  (303) 592-1010

                          NanoPierce Technologies, Inc.
              (Former name, former address or former fiscal year,
                          if changed since last report)

Check  whether  the  issuer  (1)  has  filed all reports required to be filed by
Section 13(a) or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports),  and  (2) has been subject to such filing requirements for the past 90
days.      Yes  X  No
               ---    ---

Indicate  by check mark whether the registrant is a shell company (as defined in
Rule  12b-2  of  the Exchange Act).                 Yes     No  X
                                                        ---    ---

State the number of shares outstanding of each of the issuer's classes of common
equity,  as  of  the  latest  practicable  date:

  As of February 20, 2006 there were 22,496,012 shares of the registrant's sole
                      class of common shares outstanding.

Transitional  Small  Business  Disclosure  Format          Yes     No  X
                                                               ---    ---


<PAGE>
PART I  -  FINANCIAL INFORMATION

Item  1.  Financial Statements (Unaudited)                                  Page
                                                                            ----

          Report  of  Independent  Registered  Public  Accounting  Firm      F-1

          Condensed  Consolidated  Balance  Sheet  -December 31, 2005        F-2

          Condensed  Consolidated  Statements  of  Operations  -
            Three and Six months ended December 31, 2005 and 2004            F-3

          Condensed  Consolidated  Statements  of  Comprehensive
            Loss  -  Three  and  Six  months  ended  December  31,
            2005 and 2004                                                    F-4

          Condensed  Consolidated  Statement  of  Changes  in
            Shareholders' Equity  -Six  months  ended  December  31,  2005   F-5

          Condensed  Consolidated  Statements  of  Cash  Flows -
            Six  months  ended  December  31,  2005 and 2004                 F-6

          Notes  to Condensed Consolidated Financial Statements              F-8

Item  2.  Management's  Discussion  and  Analysis                            1

Item  3.  Controls  and  Procedures                                          4

PART  II - OTHER  INFORMATION

Item  1.  Legal  Proceedings                                                 5

Item  2.  Unregistered  Sales  of  Equity  Securities  and  Use  of
            Proceeds                                                         6

Item  3.  Defaults  Upon  Senior  Securities  -  Not  Applicable

Item  4.  Submission  of  Matters to a Vote of Security Holders
            - Not Applicable

Item  5.  Other Information - Not Applicable

Item  6.  Exhibits  and  Reports  on Form 8-K                                7

       SIGNATURES                                                            9


<PAGE>
             REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
             -------------------------------------------------------


Board of Directors
Vyta Corp

We  have  reviewed the accompanying condensed consolidated balance sheet of Vyta
Corp  (formerly  known  as NanoPierce Technologies, Inc.) and subsidiaries as of
December  31,  2005, the related condensed consolidated statements of operations
and  comprehensive loss for the three-month and six-month periods ended December
31,  2005  and 2004, the condensed consolidated statements of cash flows for the
six-month  periods  ended  December  31,  2005  and  2004,  and  the  condensed
consolidated  statement  of  changes  in  shareholders' equity for the six-month
period  ended  December 31, 2005. These interim condensed consolidated financial
statements are the responsibility of the Company's management.

We  conducted our reviews in accordance with the standards of the Public Company
Accounting  Oversight  Board  (United  States).  A  review  of interim financial
information  consists  principally  of applying analytical procedures and making
inquiries  of  persons  responsible for financial and accounting matters.  It is
substantially less in scope than an audit conducted in accordance with standards
of  the Public Company Accounting Oversight Board (United States), the objective
of  which  is  the  expression  of an opinion regarding the financial statements
taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should
be  made to the accompanying interim condensed consolidated financial statements
for  them  to  be in conformity with accounting principles generally accepted in
the  United  States  of  America.



/s/ GHP HORWATH, P.C.

Denver, Colorado
February  11,  2006


                                      F-1
<PAGE>
<TABLE>
<CAPTION>
                            VYTA CORP AND SUBSIDIARIES
                 (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                       Condensed Consolidated Balance Sheet
                                 December 31, 2005
                                    (Unaudited)

                                 Assets
                                 ------
<S>                                                                  <C>
Current assets:
  Cash and cash equivalents                                          $    247,412
  Interest receivable                                                         929
  Note receivable, net (Note 2)                                           186,323
  Prepaid expenses                                                         44,976
                                                                     -------------
    Total current assets                                                  479,640
                                                                     -------------

Property and equipment:
  Office equipment and furniture                                           66,357
  Less accumulated depreciation                                           (53,367)
                                                                     -------------
                                                                           12,990
                                                                     -------------

Other assets:
  Deposits and other                                                       19,285
  Notes receivable, affiliate (Note 2)                                    400,000
  Investments in affiliates (Note 3)                                    1,269,988
                                                                     -------------
                                                                        1,689,273
                                                                     -------------

      Total assets                                                   $  2,181,903
                                                                     =============

                 Liabilities and Shareholders' Equity
                 ------------------------------------

Current liabilities:
  Accounts payable                                                   $    160,054
  Accrued liabilities                                                      10,427
  Derivative warrant liability (Note 5)                                   154,098
  Other liabilities (Note 6)                                            1,000,000
                                                                     -------------
    Total liabilities  (all current)                                    1,324,579
                                                                     -------------

Commitments and contingencies (Notes 4 and 8)

Shareholders' equity (Note 7):
  Preferred stock; $0.0001 par value; 5,000,000 shares authorized;
    none issued and outstanding
  Common stock; $0.0001 par value; 200,000,000 shares authorized;
    7,247,327 shares issued and outstanding                                   725
  Additional paid-in capital                                           25,396,315
  Accumulated other comprehensive income                                  122,857
  Accumulated deficit                                                 (24,662,573)
                                                                     -------------
      Total shareholders' equity                                          857,324
                                                                     -------------

        Total liabilities and shareholders' equity                   $  2,181,903
                                                                     =============
</TABLE>

See notes to condensed consolidated financial statements.


                                      F-2
<PAGE>
<TABLE>
<CAPTION>
                                 VYTA CORP AND SUBSIDIARIES
                     (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                      Condensed Consolidated Statements of Operations
                                        (Unaudited)

                                           Three Months Ended          Six Months Ended
                                              December 31,               December 31,
                                        -------------------------  ------------------------
                                            2005         2004         2005         2004
                                        ------------  -----------  -----------  -----------
<S>                                     <C>           <C>          <C>          <C>
Revenues                                $         -            -            -            -
                                        ------------  -----------  -----------  -----------

General and administrative expense         (216,188)    (178,186)    (441,027)    (391,260)
                                        ------------  -----------  -----------  -----------

Loss from operations                       (216,188)    (178,186)    (441,027)    (391,260)
                                        ------------  -----------  -----------  -----------

Other income (expense):
  Other income                                    -          322       28,585       10,508
  Interest income                             4,419        4,687        8,350        6,187
  Equity losses of affiliates (Note 3)     (129,747)  (   44,391)    (389,654)     (49,297)
  Loss on revaluation of derivative
    warrant liability (Note 5)               (4,158)           -       (4,158)           -
  Interest expense                                -            -     (235,131)           -
  Interest expense, related party                 -            -         (219)           -
                                        ------------  -----------  -----------  -----------
                                           (129,486)     (39,382)    (592,227)     (32,602)
                                        ------------  -----------  -----------  -----------

Net loss                                $  (345,674)    (217,568)  (1,033,254)    (423,862)
                                        ============  ===========  ===========  ===========

Net loss per share, basic and diluted
  (Note 1)                              $     (0.05)       (0.05)       (0.16)       (0.09)
                                        ============  ===========  ===========  ===========

Weighted average number of common
  shares outstanding (Note 1)             6,855,418    4,548,386    6,327,884    4,525,670
                                        ============  ===========  ===========  ===========
</TABLE>

See notes to condensed consolidated financial statements.


                                      F-3
<PAGE>
<TABLE>
<CAPTION>
                             VYTA CORP AND SUBSIDIARIES
                  (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
               Condensed Consolidated Statements of Comprehensive Loss
                                     (Unaudited)

                                  Three Months Ended          Six Months Ended
                                      December 31,               December 31,
                              --------------------------  --------------------------
                                  2005          2004          2005          2004
                              ------------  ------------  ------------  ------------
<S>                           <C>           <C>           <C>           <C>
Net loss                      $  (345,674)     (217,568)   (1,033,254)     (423,862)

Change in unrealized loss on
  securities                            -           (47)          (14)         (295)
                              ------------  ------------  ------------  ------------

Comprehensive loss            $  (345,674)     (217,615)   (1,033,268)     (424,157)
                              ============  ============  ============  ============
</TABLE>

See notes to condensed consolidated financial statements.


                                      F-4
<PAGE>
<TABLE>
<CAPTION>
                                         VYTA CORP AND SUBSIDIARIES
                             (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                    Condensed Consolidated Statement of Changes in Shareholders' Equity
                                     Six Months Ended December 31, 2005
                                                (Unaudited)

                              Common stock     Additional   Accumulated other                    Total
                           ------------------    paid-in      comprehensive    Accumulated   shareholders'
                            Shares    Amount     capital         income          deficit         equity
                           ---------  -------  -----------  -----------------  ------------  --------------
<S>                        <C>        <C>      <C>          <C>                <C>           <C>
Balances, July 1, 2005
  (Note 1)                 4,662,952  $   466  24,059,377             122,843  (23,629,319)        553,367

Common stock issued upon
  exercise of warrants,
  net of offering costs
  (Notes 6 and 7)          1,535,000      154     734,846                   -            -         735,000

Common stock issued upon
  issuance of notes
  payable
  (Notes 4 and 7)            455,000       46     117,840                   -            -         117,886

Common stock and
  warrants issued for
  cash (Notes 5 and 7)       544,375       54     316,107                   -            -         316,161

Common stock and
  warrants to be issued            -        -      71,400                   -            -          71,400

Common stock issued as
  payment of commission       50,000        5      89,995                   -            -          90,000

Forgiveness of accrued
  payroll owed to
  officer /shareholder             -        -       8,750                   -            -           8,750

Receivable for issuance
  of common stock
  (Note 7)                         -        -      (2,000)                  -            -          (2,000)

Net loss                           -        -           -                   -   (1,033,254)     (1,033,254)

Other comprehensive
  loss:
    Change in unrealized
      gain on securities           -        -           -                  14            -              14
                           ---------  -------  -----------  -----------------  ------------  --------------
Balances,
  December 31, 2005        7,247,327  $   725  25,396,315             122,857  (24,662,573)        857,324
                           =========  =======  ===========  =================  ============  ==============
</TABLE>

See notes to condensed consolidated financial statements.


                                      F-5
<PAGE>
<TABLE>
<CAPTION>
                                VYTA CORP AND SUBSIDIARIES
                     (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                      Condensed Consolidated Statements of Cash Flows
                                        (Unaudited)

                                                                     Six Months Ended
                                                                       December 31,
                                                               ---------------------------
                                                                   2005           2004
                                                               -------------  ------------
<S>                                                            <C>            <C>
Cash flows from operating activities:
  Net loss                                                     $ (1,033,254)     (423,862)
                                                               -------------  ------------
  Adjustments to reconcile net loss to net cash used
    in operating activities:
    Amortization expense                                             45,370             -
    Depreciation expense                                              2,853         3,628
    Equity losses of affiliates                                     389,654        49,297
    Amortization of discounts on notes payable                      213,760             -
    Loss on revaluation of derivative warrant
      liability (Note 5)                                              4,158             -
    Changes in operating assets and liabilities:
      Decrease in interest receivable                                 2,894         2,061
      Decrease in prepaid expenses                                      960        42,254
      (Decrease) increase in accounts payable and accrued
        liabilities                                                 (53,774)       12,496
                                                               -------------  ------------
  Total adjustments                                                 605,875       109,736
                                                               -------------  ------------

        Net cash used in operating activities                      (427,379)     (314,126)
                                                               -------------  ------------

Cash flows from investing activities:
    Increase in notes receivable                                   (400,000)     (349,000)
    Increase in advance receivable                                        -      (150,000)
    Payment on note receivable                                       89,119             -
    Investment in joint venture (Note 3)                           (500,000)            -
                                                               -------------  ------------
        Net cash used in investing activities                      (810,881)     (499,000)
                                                               -------------  ------------

Cash flows from financing activities:
    Exercise of warrants and common stock and warrants
      issued for cash                                             2,070,500       112,801
    Proceeds to be applied to preferred stock
      purchase (Note 6)                                             200,000             -
    Payment of notes payable                                       (960,663)      (46,052)
    Proceeds from issuance of notes payable and common stock        150,000             -
                                                               -------------  ------------
        Net cash provided by financing activities                 1,459,837        66,749
                                                               -------------  ------------

Net increase (decrease) in cash and cash equivalents                221,577      (746,377)

Cash and cash equivalents, beginning                                 25,835     1,018,408
                                                               -------------  ------------

Cash and cash equivalents, ending                              $    247,412       272,031
                                                               =============  ============
</TABLE>

                                  (Continued)
                                      F-6
<PAGE>
<TABLE>
<CAPTION>
                            VYTA CORP AND SUBSIDIARIES
                 (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                  Condensed Consolidated Statements of Cash Flows
                                    (Unaudited)
                                     Continued

                                                                  Six Months Ended
                                                                    December 31,
                                                               ---------------------
                                                                  2005        2004
                                                               -----------  --------
<S>                                                            <C>          <C>
Supplemental disclosure of cash flow information:
  Cash paid for interest                                       $     1,069         -
                                                               ===========  ========

Supplemental disclosure of non-cash investing and financing
  activities:
    Issuance of common stock in connection with notes payable  $   117,886         -
                                                               ===========  ========
    Issuance of common stock in exchange for accrued
      commissions                                              $    90,000         -
                                                               ===========  ========
    Advances receivable applied to equity investment           $   405,000         -
                                                               ===========  ========
    Equity investment acquired in exchange for note payable    $   595,000         -
                                                               ===========  ========
    Liability recorded for offering costs of common
      stock issuance                                           $   800,000         -
                                                               ===========  ========
    Forgiveness of accrued payroll owed to
      officer/shareholder                                      $     8,750         -
                                                               ===========  ========
    Issuance of common stock in exchange for receivable        $     2,000         -
                                                               ===========  ========
</TABLE>

See notes to condensed consolidated financial statements.


                                      F-7
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

1.     BUSINESS,  ORGANIZATION  AND  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

PRESENTATION OF INTERIM INFORMATION:

The  accompanying  condensed  consolidated  financial  statements  include  the
accounts  of  NanoPierce  Technologies,  Inc.,  a  Nevada  corporation, which on
January  31,  2006 changed its name to Vyta Corp (the Company), its wholly-owned
subsidiaries,  NanoPierce Connection Systems, Inc., a Nevada corporation (NCOS),
and  ExypnoTech,  LLC  (ET LLC), a Colorado limited liability company, which was
formed  in  June  2004.  All  significant intercompany accounts and transactions
have  been  eliminated  in  consolidation.

On  January 19, 2006, the Company's Board of Directors (the "Board") approved an
amendment  to the Company's Articles of Incorporation to effect a one-for-twenty
reverse  stock  split  effective  January  31,  2006.  All references to shares,
options, and warrants in the three and six months ended December 31, 2005 and in
prior periods, have been adjusted to reflect the post-reverse split amounts. The
Company's  common  stock now trades on the Over-the-Counter Bulletin Board under
the  trading  symbol  "VYTC".

As  a  result of the reverse split, the Company's authorized capital was reduced
from 200,000,000 shares to 10,000,000 shares.  As part of the reverse split, the
Company  amended  and  restated  its  Articles  of Incorporation to increase the
authorized  capital  of  the  Company  to  200,000,000  shares.

In  the  opinion  of  the  management of the Company, the accompanying unaudited
condensed  consolidated  financial  statements include all material adjustments,
including  all normal and recurring adjustments, considered necessary to present
fairly  the  financial  position  and  operating  results of the Company for the
periods  presented.  The  financial  statements  and  notes  are  presented  as
permitted by Form 10-QSB, and do not contain certain information included in the
Company's  Annual Report on Form 10-KSB for the fiscal year ended June 30, 2005.
It  is the Company's opinion that when the interim financial statements are read
in  conjunction  with  the  June  30,  2005  Annual  Report  on Form 10-KSB, the
disclosures  are  adequate  to  make  the  information presented not misleading.
Interim results are not necessarily indicative of results for a full year or any
future  period.


                                      F-8
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

MANAGEMENT'S  PLANS:

In the Company's Annual Report on Form 10-KSB for the fiscal year ended June 30,
2005,  the  Report of the Independent Registered Public Accounting Firm includes
an  explanatory  paragraph  that describes substantial doubt about the Company's
ability  to  continue  as  a  going  concern.  The  Company's  interim financial
statements  for  the  six  and  three  months  ended December 31, 2005 have been
prepared  on a going concern basis, which contemplates the realization of assets
and  the  settlement  of  liabilities  and  commitments  in the normal course of
business.  The  Company  reported  a  net  loss of $1,033,254 for the six months
ended  December  31,  2005,  and  an  accumulated  deficit  of $24,662,573 as of
December  31,  2005.  The  Company  has  not  recognized  any  revenues from its
business  operations.

These factors raise substantial doubt about the Company's ability to continue as
a  going  concern.  The  financial  statements  do  not  contain any adjustments
relating  to  the recoverability and classification of assets or the amounts and
classification  of  liabilities  that  might  be necessary should the Company be
unable  to  continue  as  a  going  concern.

Currently,  the  Company  does  not  have  a  revolving  loan agreement with any
financial institution, nor can the Company provide any assurance it will be able
to  enter  into  any  such  agreement  in  the future, or be able to raise funds
through  a  further  issuance  of  debt  or  equity  in  the  Company.

RECENT  EVENTS:

In August 2005, the Company was able to raise $1,535,000 through the exercise of
1,535,000  warrants  with an exercise price of $1.00 per share. The Company used
$1,095,000 of the funds to complete its purchase of a 50% equity investment in a
joint  venture,  BioAgra,  LLC,  a  Georgia  limited  liability  company
("BioAgra")(Note  3),  and  the  Company  used  approximately  $366,000  to  pay
outstanding  notes  payable  (Note 4). The remaining $75,000 was used to support
operations.

In  September  2005,  the Company executed a subscription agreement with Arizcan
Properties,  Ltd.  ("Arizcan")  to sell shares of the Company's preferred stock.
The  sole  director  of  Arizcan  is  related  to  a board member and officer of
Intercell  International  Corporation  ("Intercell"), in which the Company has a
nominal  interest.  Ms.  Kampmann,  the  Company's  Chief Financial Officer, has
served  as  the  Chief Financial Officer of Intercell since October 2003 and Mr.
Metzinger,  the Company's Chief Executive Officer, served as the Chief Executive
Officer  of  Intercell  from  September  2004  until  March  2005.


                                      F-9
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

The subscription agreement provides for the sale of 200,000 shares of Class A 8%
cumulative  and  participating  preferred shares for $7.50 per share. In January
2006,  Arizcan  purchased  200,000  shares of the Company's Series A Convertible
Preferred  Stock  ("Preferred  Stock")  for  $400,000  cash  and  an  unsecured
promissory  note  for  $1,100,000.  The promissory note bears interest at 8% per
annum  and  is  due  in  January  2007.  In February 2006, Arizcan converted the
200,000  shares  of  preferred  stock  into  15,000,000  shares of the Company's
restricted  common stock. Upon the conversion, Arizcan held approximately 67% of
the  issued  and outstanding common stock of the Company. The conversion feature
was  deemend  beneficial  and  accordingly  resulted  in a beneficial conversion
feature  of $1,500,000. The intrinsic value of the beneficial conversion feature
is limited to the total amount of the proceeds received.

DEFERRED CONSULTING COSTS:

In  June  2005,  the  Company  entered  into  a twelve-month consulting services
agreement  with  a third party, in which this party agreed to provide public and
investor  relation  services  and general business services for the twelve-month
term  of the agreement. Compensation consisted of 50,000 shares of the Company's
restricted  common  stock with a market value of approximately $90,000 (based on
the closing market price of $1.80 per share at the date of the transaction). The
deferred  cost is being amortized on a straight-line basis over the twelve-month
period  from the date of the agreement. During the six months ended December 31,
2005,  $45,370  was  expensed.

LOSS PER SHARE:

Statement  of Financial Accounting Standards (SFAS) No. 128, Earnings Per Share,
requires dual presentation of basic and diluted earnings or loss per share (EPS)
with  a  reconciliation  of  the  basic  EPS  computation  to  the numerator and
denominator  of  the  diluted  EPS  computation.  Basic  EPS  excludes dilution.
Diluted  EPS  reflects  the potential dilution that could occur if securities or
other  contracts  to  issue common stock were exercised or converted into common
stock  or  resulted  in  the  issuance  of  common stock that then shared in the
earnings of the entity.  Loss per share of common stock is computed based on the
weighted  average  number of common shares outstanding during the period.  Stock
options and warrants are not considered in the calculation, as the impact of the
potential  common  shares  (1,926,877  shares at December 31, 2005 and 3,809,094
shares  at  December  31, 2004) would be to decrease loss per share.  Therefore,
diluted  loss  per  share  is  equivalent  to  basic  loss  per  share.

ACCOUNTING  FOR OBLIGATIONS AND INSTRUMENTS POTENTIALLY SETTLED IN THE COMPANY'S
COMMON  STOCK:

The  Company  accounts for obligations and instruments potentially to be settled
in  the  Company's stock in accordance with EITF Issue No. 00-19, ACCOUNTING FOR
DERIVATIVE  FINANCIAL  INSTRUMENTS  INDEXED  TO,  AND  POTENTIALLY  SETTLED IN A
COMPANY'S  OWN  STOCK.  This  issue  addresses  the  initial  balance  sheet
classification and measurement of contracts that are indexed to, and potentially
settled in, the Company's stock.


                                      F-10
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

Under  EITF  00-19,  contracts  are  initially classified as equity or as either
assets  or  liabilities, depending on the situation. All contracts are initially
measured  at fair value and subsequently accounted for based on the then current
classification.  Contracts  initially  classified  as  equity  do  not recognize
subsequent  changes  in  fair  value  as  long  as  the contracts continue to be
classified  as  equity.  For  contracts classified as assets or liabilities, the
Company  reports changes in fair value in earnings and disclose these changes in
the financial statements as long as the contracts remain classified as assets or
liabilities.  If  contracts  classified  as assets or liabilities are ultimately
settled  in  shares,  any previously reported gains or losses on those contracts
continue  to  be  included  in  earnings.  The  classification  of a contract is
reassessed  at  each  balance  sheet  date.

STOCK-BASED COMPENSATION:

SFAS  No.  123,  Accounting  for  Stock  Based Compensation, allows companies to
choose  whether to account for employee stock-based compensation on a fair value
method,  or  to  continue  accounting  for such compensation under the intrinsic
value  method  prescribed  in  Accounting  Principles  Board  Opinion  No.  25,
Accounting  for  Stock  Issued to Employees (APB 25).  The Company has chosen to
continue  to  account  for  employee  stock-based  compensation  using  APB  25.

No  options  were  granted to employees during the six months ended December 31,
2005  or  2004.

RECENTLY  ISSUED  ACCOUNTING  STANDARD:

In  December  2004,  the Financial Accounting Standards Board (FASB) issued SFAS
No.  123(R), Share-Based Payment, which addresses the accounting for share-based
payment  transactions.  SFAS  No.  123(R)  eliminates the ability to account for
share-based  compensation  transactions  using  APB  25,  and generally requires
instead  that  such transactions be accounted and recognized in the statement of
operations  based  on  their  fair value.  SFAS No. 123(R) will be effective for
public  companies that file as small business issuers as of the beginning of the
next annual reporting period that begins after December 15, 2005.  Management is
currently evaluating the provisions of this standard.  Depending upon the number
of  and  terms  of  options  that  may  be  granted  in  future  periods,  the
implementation of this standard could have a significant impact on the Company's
financial  position  and  results  of  operations  in  future  periods.


                                      F-11
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

2.     NOTES  AND  ADVANCES  RECEIVABLE:

In  December 2005, the Company loaned $400,000 to BioAgra (Note 3).  In exchange
for  the loan, the Company received a secured, 7.5% promissory note, due on June
30, 2006.  The funds were loaned to facilitate BioAgra's completion of its first
production  line  and  the purchase of inventory for production.  The promissory
notes  are  collateralized  by  all  equipment,  furnishings, present and future
accounts,  collateral  securing  such accounts, tangible and intangible personal
property  and  any  proceeds  from  any  of  the  foregoing located on BioAgra's
premises.  Additionally,  the  promissory  notes are to be paid in full prior to
any disbursements being made to the members of the joint venture. During January
2006,  the  Company loaned an additional $200,000 to BioAgra with the same terms
as  the  original  promissory  notes.  During  February 2006, the Company loaned
BioAgra  an  additional $100,000, with the same terms as the original promissory
notes.

In  November  2004, the Company loaned $314,000 to Arizcan.  In exchange for the
loan,  the  Company  received an unsecured, 7% promissory note, which was due on
October  31, 2005.  The funds were loaned to facilitate Arizcan's purchase of an
option  from  certain of the Company's warrant holders, to initiate the exercise
of  certain  existing warrants to purchase up to 785,000 shares of the Company's
common stock (Note 6).  In June 2005, the Company received a payment of $50,000,
which  included  interest  of $11,442.  In December 2005, the Company received a
payment  of  $100,000, which included interest of $10,881. During February 2006,
the  Company  received a payment of $100,000, which included interest of $2,073.
The  remaining  balance of this note ($88,396) remains outstanding and is due on
demand.

In  October  and November 2004, the Company advanced a total of $150,000 to Xact
Resources  International,  Inc.  ("Xact  Resources"),  which  was applied to the
purchase  of  a  50%  equity  interest  in  BioAgra on August 15, 2005 (Note 3).

In  December  2004,  the  Company  loaned  $35,000 to Intercell in return for an
unsecured, 7% promissory note, due in December 2005.  The loan was made in order
to  assist  Intercell  in  its  efforts to support operations.    In March 2005,
Intercell  filed  for  protection  under Chapter 11 of the U.S. Bankruptcy Code.
During  the  fiscal  year  ended  June  30,  2005,  the  Company deemed the debt
uncollectible  and  created  an  allowance  for  the  receivable  of  $35,000.


                                      F-12
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

3.     INVESTMENTS IN AFFILIATES:

INVESTMENT IN EXYPNOTECH, GMBH:

In  December  2003,  TagStar  Systems,  Gmbh,  a  German entity formed by former
employees  of  ExypnoTech,  Gmbh  ("EPT"),  purchased  a  controlling 51% equity
interest  in  EPT  in  exchange  for $98,000, of which $62,787 has been received
through  December 31, 2005. The Company accounts for its investment in EPT under
the  equity  method  of  accounting.  Under the equity method of accounting, the
carrying  amount  of  the  Company's investment in EPT ($112,404 at December 31,
2005) is adjusted to recognize the Company's proportionate share of EPT's income
(loss)  each  period.

Unaudited  financial information of EPT as of December 31, 2005, and for the six
and  three-month  periods  ended  December  31,  2005  and  2004 are as follows:

<TABLE>
<CAPTION>
                                                          December 31,
                                                              2005
                                                          ------------
<S>                                                       <C>
          Assets:
              Current assets(1)                           $    381,042
              Equipment                                        135,336
                                                          ------------

            Total assets                                  $    516,378
                                                          ============

          Liabilities and members' equity:
              Current liabilities(2)                      $    438,301
              Members' equity                                   78,077
                                                          ------------

          Total liabilities and members' equity           $    516,378
                                                          ============
</TABLE>

          (1)     Current assets include receivables of $44,117 due from the 51%
                  owner of EPT.
          (2)     Current liabilities include a payable of $14,412 due to the
                  51% owner of EPT.

<TABLE>
<CAPTION>
                 Three Months Ended              Six Months Ended
                      December 31,                 December 31,
                  2005           2004          2005           2004
             --------------  ------------  -------------  ------------
<S>          <C>             <C>           <C>            <C>
Revenues(1)  $     645,460        60,434      1,045,196       144,859
Expenses(2)       (707,287)     (121,487)    (1,141,600)     (197,839)
             --------------  ------------  -------------  ------------
Net loss     $     (61,827)      (61,053)       (96,404)      (52,980)
             ==============  ============  =============  ============
</TABLE>

     (1)  Revenues  include  $1,045,122  and  $9,562  of  sales to the 51% owner
          of  EPT  for  the  six  months  ended  December  31,  2005  and  2004,
          respectively  ($272,327 and $9,562 for the three months ended December
          31, 2005 and 2004, respectively).
     (2)  Expenses  include  $45,671  and  $19,070,  respectively  of  charges
          paid  to  the  51%  owner of EPT for the six months ended December 31,
          2005  and 2004, respectively ($37,756 and $19,070 for the three months
          ended December 31, 2005 and 2004, respectively).


                                      F-13
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

EPT  operations  are  located  in  Germany.  EPT  transactions  are conducted in
currencies  other  than  the  U.S.  dollar,  (the  currency  into  which  the
subsidiaries'  historical  financial  statements have been translated) primarily
the  Euro.  As  a result, the Company is exposed to adverse movements in foreign
currency  exchange  rates.

In  addition,  the Company is subject to risks including adverse developments in
the  foreign  political  and  economic  environments,  trade  barriers, managing
foreign  operations  and  potentially adverse tax consequences.  There can be no
assurance  that  any of these factors will not have a material adverse effect on
the  Company's  financial  condition  or  results  of  operations in the future.

INVESTMENT IN BIOAGRA:

On  August  15,  2005,  the  Company  entered  into  a  joint  venture with Xact
Resources,  a  privately  held  company.  The  Company  purchased  a  50% equity
interest  in  the  joint  venture, BioAgra, for $905,000 in cash (which includes
$405,000  previously  advanced to Xact Resources as of June 30, 2005) and a note
payable  of  $595,000, which was paid in full on September 15, 2005.  BioAgra is
to  manufacture  and  sell  a  beta  glucan  product,  YBG-2000  also  known  as
AgraStimTM,  to  be  used  as  a  replacement  for  hormone  growth steroids and
antibiotics  in  products  such  as  poultry  feed.

BioAgra  (a  development  stage  company)  is  in  the process of constructing a
production  line. BioAgra expects to begin producing and shipping product during
the quarter ending March 31, 2006.

As  consideration for Arizcan's efforts to assist NanoPierce with its efforts to
obtain  equity financing, the Company entered into an agreement with Arizcan, in
which the Company is to pay to Arizcan 20% of any cash distributions paid to the
Company  by and from BioAgra, until such time as Arizcan shall be paid $800,000
(Note 6).

The  terms of the joint venture provide for the Company to share in 50% of joint
venture  net  income,  if any, or net losses.  The Company is accounting for its
investment in BioAgra as an equity method investment.  At December 31, 2005, the
Company's  investment  in  BioAgra  is  $1,157,584.


                                      F-14
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

Unaudited  financial  information of BioAgra as of December 31, 2005 and for the
three  month  period ended December 31, 2005 and the period from August 15, 2005
through  December  31,  2005,  is  as  follows:

<TABLE>
<CAPTION>
                                                               December 31,
                                                                   2005
                                                               ------------
<S>                                                            <C>
          Assets:
              Current assets                                   $    137,417
              Equipment, net                                      1,222,047
              Land and building under capital lease, net          1,135,742
                                                               ------------

            Total assets                                       $  2,495,206
                                                               ============

          Liabilities and members' equity:
              Current liabilities(1)                           $    653,390
              Obligation under capital lease(2)                   1,026,648
                                                               ------------

            Total liabilities                                     1,680,038

              Members' equity                                       815,168
                                                               ------------

          Total liabilities and members' equity                $  2,495,206
                                                               ============
</TABLE>

          (1)  Includes $400,000 owed to the Company.
          (2)  BioAgra  leases  land  and  a  building  under  a  ten-year lease
               expiring in February 2015, which requires a monthly lease payment
               of $12,000.

<TABLE>
<CAPTION>
                                               August 15, 2005
                        Three Months Ended         through
                        December 31, 2005     December 31, 2005
                        -------------------  -------------------
<S>                     <C>                  <C>
     Revenues           $                -   $                -
     Expenses                     (198,902)            (684,832)
                        -------------------  -------------------
     Net loss           $         (198,902)  $         (684,832)
                        ===================  ===================
</TABLE>

INVESTMENT  IN  SCIMAXX  SOLUTIONS,  LLC:

On  September  15,  2003, the Company entered into an agreement to receive a 50%
interest  in a joint venture agreement with Scimaxx, LLC.  The name of the joint
venture  was  Scimaxx  Solutions,  LLC  (Scimaxx Solutions).  The purpose of the
joint  venture  was to provide the electronics industry with technical solutions
to  manufacturing  problems  based  on  the  need  for  electrical connectivity.

At December 31, 2004, Scimaxx Solutions had total assets of $79,664 of which
$607 were current assets and $79,057 were equipment, total liabilities of
$61,619 and members' equity of $18,045.


                                      F-15
<PAGE>

                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

For the three and six months ended December 31, 2004, Scimaxx Solutions recorded
revenues  of  $0  and $5,721, respectively, and expenses of $21,623 and $53,320,
respectively,  resulting  in  a  net  loss of $21,623 and $47,599, respectively.
Scimaxx  Solutions  ceased  operations  in  April  2005.

4.     NOTES AND ADVANCES PAYABLE:

RELATED PARTIES:

In  June  2005, an officer/director of the Company loaned $41,000 to the Company
in  exchange  for  an  unsecured, 5% note payable due in December 2005.  In June
2005,  the  Company paid $337 plus accrued interest of $17.  In August 2005, the
Company  paid  the  remaining  $40,663  plus  accrued  interest  of  $298.

OTHER:

In  June  2005, an unrelated party loaned the Company $25,000 in exchange for an
unsecured,  8%  promissory  note  due  in December 2005 and 75,000 shares of the
Company's  restricted  common stock, which were issued in July 2005.  The common
stock had a market value of $150,000 (based on the closing market price of $2.00
per share on the date of the transaction). The relative fair value of the common
stock  ($21,428)  was accounted for as a discount against the face amount of the
note.  The effective interest rate on this note was 85%.  On August 8, 2005, the
Company paid the $25,000, plus accrued interest of $208.  Through that date, the
discount  of  $21,428  was  fully  amortized  to  interest  expense.

In  June  2005, an unrelated third party loaned the Company $150,000 in exchange
for an unsecured, promissory note due in September 2005 with interest at 15% per
quarter  and  100,000  shares  of  the Company's restricted common stock (50,000
shares  were  issued in June 2005 and the remaining 50,000 shares were issued in
July  2005).  At  the  date  of issuance, the common stock had a market value of
$180,000  (based  on  the closing market price of $1.80 per share on the date of
the  transaction).  The  relative  fair  value  of the common stock($81,718) was
accounted  for  as  a discount applied against the face amount of the note.  The
effective  interest  rate  on this note was 54%.  As of June 30, 2005, $7,272 of
the  discount had been amortized to interest expense.  On September 8, 2005, the
Company paid the $150,000, plus accrued interest of $22,500.  Through that date,
the  remaining  discount  of  $74,446  was  fully amortized to interest expense.


                                      F-16
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

During  July  and  August 2005, six unrelated third parties loaned the Company a
total of $150,000 in exchange for unsecured, 8% promissory notes due in December
2005  and  a  total  of 330,000 shares of the Company's restricted common stock.
The  common  stock  had  a  total market value of $574,000 (based on the closing
market  prices  which  ranged  from $1.60 to $1.80 per share at the date of each
transaction).  The  relative  fair  value  of  the  common  stock ($117,886) was
accounted  for  as a discount applied against the face amount of the notes.  The
discount  was  amortized  over  the  terms of the promissory notes as additional
interest expense.  The effective interest rate on these notes is 85%.  On August
8,  2005, the Company paid the $150,000, plus accrued interest of $642.  Through
that  date,  the  discount  of $117,886 was fully amortized to interest expense.

5.     DERIVATIVE  WARRANT  LIABILITY:

During  November  and  December  2005,  the  Company  sold 500,625 shares of its
restricted  common  stock  for  $400,500.  In  connection  with  the sale of the
restricted  common shares, the Company agreed to issue warrants exercisable into
500,625  shares  of  the  Company's  common  stock. The common stock had a total
market  value  of $714,125 (based on the closing market prices which ranged from
$1.00  to  $1.60 per share at the date of each transaction). The warrants had an
aggregate  estimated fair value of $312,167 (using the Black-Scholes model). The
relative  fair value of the warrants ($119,339) was accounted for as a liability
in  accordance  with EITF 00-19, as the Company's authorized and unissued shares
available  to  settle the warrants (after considering all other commitments that
may  require  the  issuance of stock during the maximum period the warrant could
remain  outstanding)  were  determined  to  be  insufficient.

During  December  2005, the Company sold 127,500 shares of its restricted common
stock  for  $102,000. These shares of common stock were not issued until January
2006.  In  connection with the sale of the restricted common shares, the Company
agreed  to issue warrants exercisable for 127,500 shares of the Company's common
stock.  The  common  stock  had  a  total market value of $178,000 (based on the
closing  market prices which ranged from $1.20 to $1.60 per share at the date of
each transaction). The warrants had an aggregate estimated fair value of $76,657
(using  the  Black-Scholes  model).  The  relative  fair  value  of the warrants
($30,600) was accounted for as a liability in accordance with EITF 00-19, as the
Company's authorized and unissued shares available to settle the warrants (after
considering  all other commitments that may require the issuance of stock during
the  maximum  period the warrant could remain outstanding) were determined to be
insufficient.

In  February 2006, after the effectiveness of the reverse split and the increase
in  authorized shares, the fair value of the warrants was reclassified to equity
in  accordance  with  EITF  00-19.


                                      F-17
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

The  fair  value of the warrants are evaluated at each reporting period with any
resulting  change  in  fair  value being reflected in the condensed consolidated
statement  of  operations.  The  Company recognized a loss of $4,158 for the six
months  ended  December  31,  2005,  due  to the change in the fair value of the
warrants  from  the  date  of  issuance. At December 31, 2005, the warrants fair
value  is  estimated  to  be  $154,098.

6.     OTHER  LIABILITIES

The  Company  has  recorded an $800,000 payable to Arizcan, which represents the
costs  incurred in connection with a $1.5 million offering of equity securities.

In  December  2005,  the  Company received an advance payment of $200,000 on the
purchase  of  200,000  shares  of its Series A Convertible Preferred Shares from
Arizcan.  The  Company  recorded  the advance as a liability and agreed to apply
the  advance  to  the  final purchase of the Preferred Shares.  In January 2006,
Arizcan  completed  the  purchase  of  the  Preferred  Shares.

7.     SHAREHOLDERS' EQUITY:

COMMON STOCK:

Current Year Transactions

In  connection with the issuance of a $150,000 promissory note in June 2005, the
Company agreed to issue 100,000 shares of its restricted common stock, valued at
$81,718, of which 50,000 shares were issued in June 2005, and 50,000 shares were
issued  in  July  2005.

In  connection  with the issuance of a $25,000 promissory note in June 2005, the
Company  agreed to issue 75,000 shares of its restricted common stock, valued at
$21,428,  which  were  issued  in  July  2005.

During July and August 2005, in connection with the issuance of promissory notes
totaling  $150,000,  the  Company issued 330,000 shares of its restricted common
stock,  valued  at  $117,886.

In  August  2005,  warrants  to  purchase  1,535,000 shares of common stock were
exercised  for  cash  proceeds of $1,535,000 in exchange for 1,535,000 shares of
common  stock.  The  exercise price of these warrants was lowered from $2.00 and
$3.00  per  share  to  $1.00  per  share  in  connection  with  the  exercise.

In  October  2005,  the  Company  issued  50,000 shares of its restricted common
stock,  valued  at  $90,000,  in satisfaction of a $90,000 liability incurred in
connection  with  the  Company's  financing  efforts.

During  October  2005, the Company issued 43,750 shares of its restricted common
stock  in  exchange  for  $35,000.  The shares had a purchase price of $0.80 per
share  (based  on a 50% discount from the closing market price, $1.60 per share,
on  the  date  of  each  transaction).


                                      F-18
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

During  November  and  December  2005,  the Company issued 500,625 shares of its
restricted  common  stock  and  warrants  to  purchase  500,625  shares  of  its
restricted common stock for $400,500, of which $2,000 was recorded as receivable
for  the  issuance  of  common  stock at December 31, 2005. The warrants have an
exercise  price  of  $1.00 per share and a term of 3 years. The shares of common
stock  had  a  purchase  price  of  $0.80  share and are to be registered by the
Company  with  the  Securities  and  Exchange  Commission  (SEC).

During  December  2005, the Company sold 127,500 shares of its restricted common
stock  for  $102,000. These shares of common stock were not issued until January
2006.  In  connection with the sale of the restricted common shares, the Company
agreed  to issue three-year warrants to purchase 127,500 shares of the Company's
common stock at $1.00 per share. The shares of common stock had a purchase price
of $0.80 share and are to be registered by the Company with the SEC.

In  January  2006,  the  Company  issued 118,592 shares of its restricted common
stock and warrants to purchase 118,592 shares of its restricted common stock for
$94,873.  The  warrants  have an exercise price of $1.00 per share and a term of
three years.  The shares of common stock had a purchase price of $0.80 per share
and are to be registered by the Company with the SEC.

Six Months Ended December 31, 2004

During  the six months ended December 31, 2004, the Company issued 60,000 shares
of  common  stock  upon the exercise of warrants.  The Company received net cash
proceeds  of  $112,801  (net  of  $7,200  of  offering  costs).

WARRANTS:

During  the  six  months  ended  December 31, 2005, warrants to purchase 117,709
shares  of  common  stock  expired.

In  December  2005  warrants  to  purchase  238,667  shares of common stock were
canceled  by  their  holders.  The  warrants  were cancelled to reduce the total
dilutive  securities  below  the authorized share limit, to allow the Company to
enter  into  additional  equity  financing  in December 2005.  In return for the
cancellation  of such warrants, the Company agreed to issue warrants to purchase
3,500,000  common shares.  The warrants have an exercise price of $1.00 and have
a  term  of  3  years.  These  warrants  were  issued  in  February  2006.

OPTIONS:

In  December  2005,  officers  and  a  director  of the Company agreed to cancel
options  under the Company's 1998 Compensatory Stock Option Plan exercisable for
31,250  shares  of  the  Company's  stock.


                                      F-19
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

In January 2006, an officer and director of the Company agreed to cancel options
under  the  Company's 1998 Compensatory Stock Option Plan exercisable for 15,000
shares  of  the  Company's  stock.

The  officers  and  director did not receive any consideration in return for the
cancellations.

CAPITAL  TRANSACTION:

In  August 2005, an officer/shareholder of the Company forgave $8,750 of accrued
salary,  which  has been accounted for as a capital transaction and has resulted
in  an  increase  in  additional  paid  in  capital.

8.     COMMITMENTS AND CONTINGENCIES

LITIGATION:

Depository  Trust  Suit:

In  May  2004,  the Company filed suit against the Depository Trust and Clearing
Corporation  ("DTCC"),  the  Depository  Trust Company ("DTC"), and the National
Securities  Clearing  Corporation ("NSCC") in the Second Judicial District Court
of  the  County  of  Washoe,  State of Nevada.  The suit alleges multiple claims
under  the  Nevada  Revised  Statutes 90.570, 90.580, 90.660 and 598A.060 and on
other  legal  bases.  The  complaint alleges, among other things, that the DTCC,
DTC  and NSCC acted in concert to operate the "Stock Borrow Program," originally
created  to address short term delivery failures by sellers of securities in the
stock  market.  According  to the complaint, the DTCC, NSCC and DTC conspired to
maintain  significant  open  fail deliver positions of millions of shares of the
Company's  common  stock  for extended periods of time by using the Stock Borrow
Program  to  cover  these open and unsettled positions.  The Company was seeking
damages  in  the amount of $25,000,000 and treble damages.  Responsive pleadings
have  been  filed  by  the  defendants.  On  April 27, 2005, the court granted a
motion  to  dismiss the lawsuit. The Company has filed an appeal to overturn the
motion  to  dismiss  the  lawsuit.


                                      F-20
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2005 and 2004
                                   (Unaudited)

Financing  Agreement  Suit:

In  connection  with  a  financing  obtained  in October 2000, the Company filed
various actions in the United States District Court for the District of Colorado
against,  among others, Harvest Court, LLC, Southridge Capital Investments, LLC,
Daniel  Pickett,  Patricia  Singer and Thomson Kernaghan, Ltd. for violations of
federal  and  state  securities laws, conspiracy, aiding and abetting and common
law  fraud  among  other  claims.  As a result of various procedural rulings, in
January  2002,  the  United  States  District Court for the District of Colorado
transferred  the  case  to  the  United  States  District Court for the Southern
District  of  New  York,  New  York City, New York.  In this litigation, Harvest
Court,  LLC  filed  counterclaims  against  the Company and certain officers and
former  board  members  of the Company, and a number of unrelated third parties.
The  counterclaims  allege violations of federal securities laws and other laws.
Harvest Court, LLC is seeking various forms of relief including compensatory and
punitive  damages.  Responsive  pleadings  have been filed and the litigation is
currently  in  the  discovery  stage.

In  May  2001,  Harvest Court, LLC filed suit against the Company in the Supreme
Court  of  the State of New York, County of New York.  The suit alleges that the
Company  breached  an  October 20, 2000 Stock Purchase Agreement, by not issuing
370,945 free trading shares of the Company's common stock in connection with the
reset  provisions  of  the  Purchase  Agreement due on the second reset date and
approximately  225,012  shares  due  in  connection  with  the third reset date.
Harvest  Court,  LLC  is  seeking  the delivery of such shares or damages in the
alternative.  In August 2001, the Supreme Court of the State of New York, County
of  New York issued a preliminary injunction ordering the Company to reserve and
not  transfer the shares allegedly due to Harvest Court, LLC.  In February 2006,
the  Supreme  Court  of  the  State  of  New  York, County of New York issued an
injunction  ordering  the  Company  to  reserve 3.7% of the Company's issued and
outstanding common stock (832,029 shares at February 13, 2006).  The Company has
set  aside  these  shares.  The  Company has filed counterclaims seeking various
forms  of  relief  against  Harvest  Court,  LLC.

The Company intends to vigorously prosecute this litigation and does not believe
the  outcome  of  this  litigation  will  have  a material adverse effect on the
financial  condition,  results  of  operations  or  liquidity  of  the  Company.
However, it is too early at this time to determine the ultimate outcome of these
matters.


                                      F-21
<PAGE>
ITEM  2.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS

     Certain  statements  contained in this Form 10-QSB contain "forward-looking
statements"  within  the meaning of the Private Securities Litigation Reform Act
of  1995  and involve risks and uncertainties that could cause actual results to
differ  materially  from  the  results,  financial  or  otherwise,  or  other
expectations  described in such forward-looking statements.  Any forward-looking
statement  or statements speak only as of the date on which such statements were
made,  and  the  Company  undertakes no obligation to update any forward-looking
statement  to  reflect  events  or  circumstances  after  the date on which such
statements  are  made  or  reflect  the  occurrence  of  unanticipated  events.
Therefore, forward-looking statements should not be relied upon as prediction of
actual  future  results.

     The independent registered public accounting firm's report on the Company's
consolidated financial statements as of June 30, 2005, and for each of the years
in  the  two-year  period  then  ended,  includes  a "going concern" explanatory
paragraph,  that  describes  substantial  doubt  about  the Company's ability to
continue  as  a  going  concern.  Management's  plans  in  regard to the factors
prompting  the  explanatory  paragraph are discussed below and also in Note 1 to
the  unaudited  quarterly  Financial  Statements.

RECENT  EVENTS

     On  January  19,  2006,  the  Company's  Board approved an amendment to our
Articles  of  Incorporation  to  change  the name of the Company from NanoPierce
Technologies,  Inc.  to  Vyta  Corp.

     On January 19, 2006 the Company's Board of Directors (the "Board") approved
an amendment to our Articles of Incorporation to affect a one-for-twenty reverse
stock  split effective January 31, 2006.  All references to shares, options, and
warrants  in  the  three  and  six  months  ended December 31, 2005 and in prior
periods,  have  been  adjusted  to  reflect the post-reverse split amounts.  The
Company's  common  stock now trades on the Over-the-Counter Bulletin Board under
the  trading  symbol  "VYTC".

     On  January  19,  2006,  the  Company's  Board approved an amendment to the
Articles  of  Incorporation  to  increase  the  authorized capital of 10,000,000
common  shares  to  200,000,000  common  shares.

RESULTS  OF  OPERATIONS

     The  Company had no revenues during the three and six months ended December
31,  2005  and  2004.

     The  Company  recognized  $28,585  of  other  income,  of  which  $28,250
represented a gain on the extinguishment of liabilities.  The Company recognized
$8,350 in interest income during the six months ended December 31, 2005 compared
to  $6,187  during the six months ended December 31, 2004 ($4,419 and $4,687 for
the  three  months  ended  December  31,  2005  and  2004,  respectively).


                                       1
<PAGE>
     Total  general  and  administrative  expenses  during  the six months ended
December  31,  2005  were $441,027 compared to $391,260 for the six months ended
December 31, 2004 ($216,188 and $178,186 for the three months ended December 31,
2005 and 2004, respectively).  The increase of $49,767 is primarily attributable
to a $68,210 increase in commission fees, a $22,720 increase in consulting fees,
offset  by  a  $24,581  decrease  in  public  relations  expense.

     The  Company  recognized  interest  expense  of $235,350 for the six months
ended  December 31, 2005 (no interest expense was recognized in the three months
ended December 31, 2005).  No interest expense was recorded during the three and
six  months  ended December 31, 2004.  Of the $235,340 in interest expense, $219
represented  related  party  interest.  The  remaining  $235,131 was incurred in
connection  with  the issuance of promissory notes, which were discounted at the
time  of  issuance.  The  resulting discounts ($213,760) were amortized over the
term  of the promissory notes.  The promissory notes were paid in full in August
2005,  and  at  that  time  the  discounts  were  fully  amortized.

     During the six months ended December 31, 2005, the Company recognized a net
loss  of  $1,033,254  compared  to  a net loss of $423,862 during the six months
ended  December  31,  2004  ($345,674  and  $217,568  for the three months ended
December 31, 2005 and 2004, respectively).  The increase of $609,392, during the
six months ended December 31, 2005, is primarily attributable to the increase of
$235,350 in interest expense, as explained above and the increase of $389,654 in
losses  of  equity  investments.

LIQUIDITY  AND  FINANCIAL  CONDITION

     During  the  six  months  ended  December 31, 2005, the Company was able to
raise  $537,500 cash through the sale of 671,875 shares of its restricted common
stock  and  warrants  to purchase 628,125 shares of its restricted common stock.

     In  August  2005, the Company was able to raise $1,535,000 cash through the
exercise  of  1,535,000  warrants  with  an  exercise  price of $1.00 per share.

     In  August 2005, the Company purchased a 50% equity interest in BioAgra for
$905,000 cash (which includes the $405,000 advanced to Xact Resources during the
fiscal  year  ended June 30, 2005) and a note payable of $595,000 which was paid
in  full  in September 2005. BioAgra plans to manufacture and sell a beta glucan
product,  YBG-2000 to be marketed as AgraStimTM, to be used as a replacement for
hormone  growth  steroids  and  antibiotics  in  products  such as poultry feed.
BioAgra  anticipates  beginning  production  and sale of the beta glucan product
AgraStim during the quarter ending March 31, 2006.

     Additionally,  the  Company  entered  into  an  agreement  with  Arizcan
Properties, Ltd. ("Arizcan") whereby the Company will pay to Arizcan, 20% of any
cash  distributions  paid  to the Company by BioAgra, until such time as Arizcan
shall  be  paid  $800,000.


                                       2
<PAGE>
     In  September  2005,  the Company executed a Subscription Agreement to sell
shares of the Company's preferred stock with Arizcan. The Subscription Agreement
provides  for  the  sale  of  200,000  shares  of  a  Class  A 8% cumulative and
participating  preferred  shares  with  a  sales  price  of $7.50 per share. The
preferred  shares  are  convertible  into  60%  of  the  Company's  issued  and
outstanding  post-split  shares  of  the  Company's  common stock on the date of
conversion.  In  December  2005,  the  Company  received  an  advance payment of
$200,000 in connection with the purchase of the Preferred Shares. On January 19,
2006,  the  Company  completed the sale of 200,000 Preferred Shares for $400,000
cash  ($200,000  of  which  was  received  in  December  2005)  and an unsecured
corporate  promissory  note of $1,100,000. The promissory note is due on January
18,  2007.  In  February 2006, Arizcan converted the 200,000 shares of preferred
stock  into 15,000,000  shares  of  the  Company's restricted common stock. Upon
conversion,  Arizcan held approximately 67% of the issued and outstanding common
stock  of  the  Company.

     During the six months ended December 31, 2005, the Company used $427,379 in
operating  activities. Net cash provided by financing activities was $1,459,337;
$960,663  was  used  to  pay  notes  payable,  $2,070,500  was received from the
exercise  of warrants and the issuance of common stock and warrants and $150,000
was  received  from  notes  payable.  Net  cash used in investing activities was
$810,881;  $500,000  was used to purchase the 51% equity interest in the BioAgra
joint venture. The Company had $247,412 of cash and cash equivalents at December
31,  2005,  which  is  being  used  to  support the operations and activities of
BioAgra,  in which the Company owns a 50% equity interest. During the six months
ended  December 31, 2004, the Company used $314,126 in operating activities from
continuing  operations.  During  the  six  months  ended  December 31, 2004, the
Company  used  $46,052  to  pay  a  note  payable.

     As  of  December 31, 2005, if all existing outstanding warrants issued in a
January  2004  private placement were exercised, the Company will be required to
issue  an  additional  1,342,500  shares  of common stock, and the Company, on a
fully  diluted basis (including the reservation of 832,029 shares as required by
the  court  in the Financing Agreement Litigation), would have 29,347,244 shares
of  common  stock  issued  and  outstanding.

     As  of  December  31, 2005, if  the  warrants  issued  to  investors in the
private  placement  described  above  are  all  exercised,  the  Company  would
receive  approximately  an  additional $2,842,500.  However, no assurance can be
given  that  any  of  these  warrants  will  be  exercised.  If the warrants are
exercised, the Company has decided that it may use the additional funds received
from  the  exercise of these warrants to acquire a revenue generating company or
to  acquire  technology  complementary to the current technology of the Company,
its ownership interest in ExypnoTech and any other licensing agreements or joint
venture  agreements  that  the  Company  may  enter  in  the  future.

     The  Company  intends  to  use the funds raised through recent sales of its
restricted  common  shares and preferred shares to support the operations of the
Company  over  the  next  12  months.  Operational  plans  include  a  corporate
restructuring  in  January  2006, as discussed above, and administrative support
provided  to  BioAgra.  The Company expects to receive funds from BioAgra in the
form  of  payment  of  outstanding  promissory  notes  and  through  payments as
specified  in  the operating agreement for BioAgra.  The Company initially plans
to  use  such funds to support administrative activities.  The Company continues
to  evaluate  additional  merger  and  acquisition  opportunities.


                                       3
<PAGE>
CRITICAL ACCOUNTING POLICY

ACCOUNTING  FOR OBLIGATIONS AND INSTRUMENTS POTENTIALLY SETTLED IN THE COMPANY'S
COMMON  STOCK:

The  Company  accounts for obligations and instruments potentially to be settled
in  the  Company's own stock in accordance with EITF Issue No. 00-19, ACCOUNTING
FOR  DERIVATIVE  FINANCIAL  INSTRUMENTS INDEXED TO, AND POTENTIALLY SETTLED IN A
COMPANY'S  OWN  STOCK.  This  issue  addresses  the  initial  balance  sheet
classification and measurement of contracts that are indexed to, and potentially
settled  in,  the  Company's  own  stock.

Under  EITF  00-19  contracts  are  initially  classified as equity or as either
assets  or  liabilities, depending on the situation. All contracts are initially
measured  at fair value and subsequently accounted for based on the then current
classification.  Contracts  initially  classified  as  equity  do  not recognize
subsequent  changes  in  fair  value  as  long  as  the contracts continue to be
classified  as  equity.  For  contracts classified as assets or liabilities, the
Company  reports changes in fair value in earnings and disclose these changes in
the financial statements as long as the contracts remain classified as assets or
liabilities.  If  contracts  classified  as assets or liabilities are ultimately
settled  in  shares,  any previously reported gains or losses on those contracts
continue  to  be  included  in  earnings.  The  classification  of a contract is
reassessed  at  each  balance  sheet  date.

ITEM  3.  CONTROLS  AND  PROCEDURES

     A  review  and  evaluation  was  performed  by  the  Company's  management,
including  the Company's Chief Executive Officer (the "CEO") and Chief Financial
Officer  (the  "CFO"),  of  the effectiveness of the design and operation of the
Company's  disclosure controls and procedures as of December 31, 2005.  Based on
that  review and evaluation, the CEO and CFO have concluded that, as of the date
of  their  evaluation, the Company's current disclosure controls and procedures,
as  designed  and  implemented,  were effective.  There have been no significant
changes  in the Company's internal controls that could significantly affect such
internal  controls  subsequent  to  the date of their evaluation.  There were no
material  weaknesses identified in the course of such review and evaluation and,
therefore,  no  corrective  measures  were  taken  by  the  Company.


                                       4
<PAGE>
                           PART II - OTHER INFORMATION

ITEM 1. Legal Proceedings

Financing  Agreement  Suit:

In  connection  with  a  financing  obtained  in October 2000, the Company filed
various actions in the United States District Court for the District of Colorado
against,  among others, Harvest Court, LLC, Southridge Capital Investments, LLC,
Daniel  Pickett,  Patricia  Singer and Thomson Kernaghan, Ltd. for violations of
federal  and  state  securities laws, conspiracy, aiding and abetting and common
law  fraud  among  other  claims.  As a result of various procedural rulings, in
January  2002,  the  United  States  District Court for the District of Colorado
transferred  the  case  to  the  United  States  District Court for the Southern
District  of  New  York,  New  York City, New York.  In this litigation, Harvest
Court,  LLC  filed  counterclaims  against  the Company and certain officers and
former  board  members  of the Company, and a number of unrelated third parties.
The  counterclaims  allege violations of federal securities laws and other laws.
Harvest Court, LLC is seeking various forms of relief including compensatory and
punitive  damages.  Responsive  pleadings  have been filed and the litigation is
currently  in  the  discovery  stage.

In  May  2001,  Harvest Court, LLC filed suit against the Company in the Supreme
Court  of  the State of New York, County of New York.  The suit alleges that the
Company  breached  an  October 20, 2000 Stock Purchase Agreement, by not issuing
370,945 free trading shares of the Company's common stock in connection with the
reset  provisions  of  the  Purchase  Agreement due on the second reset date and
approximately  225,012  shares  due  in  connection  with  the third reset date.
Harvest  Court,  LLC  is  seeking  the delivery of such shares or damages in the
alternative.  In August 2001, the Supreme Court of the State of New York, County
of  New York issued a preliminary injunction ordering the Company to reserve and
not  transfer the shares allegedly due to Harvest Court, LLC.  In February 2006,
the  Supreme  Court  of  the  State  of  New  York, County of New York issued an
injunction  ordering  the  Company  to  reserve 3.7% of the Company's issued and
outstanding common stock (832,029 shares at February 13, 2006).  The Company has
set aside and reserved these shares. The Company has filed counterclaims seeking
various  forms  of  relief  against  Harvest  Court,  LLC.


                                       5
<PAGE>
                           PART II - OTHER INFORMATION

ITEM 2.   Unregistered Sales of Equity Securities and Use of Proceeds

     The  Company  made  the following unregistered sales of its securities from
October  1,  2005  through  December  31,  2005.

<TABLE>
<CAPTION>
DATE OF     TITLE OF     NO. OF
 SALE      SECURITIES    SHARES          CONSIDERATION          CLASS OF PURCHASER
--------  ------------  ---------  ---------------------------  ------------------
<S>       <C>           <C>        <C>                          <C>
10/28/05  Common Stock    625,000  $25,000                      Business Associate
----------------------------------------------------------------------------------
10/31/05  Common Stock    250,000  $10,000                      Business Associate
----------------------------------------------------------------------------------
11/2/05   Common Stock    250,000  $10,000 for 250,000 shares
          Warrant          12,500  of common stock and          Business Associate
                                   warrant for 12,500 shares
----------------------------------------------------------------------------------
11/10/05  Common Stock    125,000  $5,000 for 125,000 shares
          Warrant           6,250  of common stock and          Business Associate
                                   warrant for 6,250 shares
----------------------------------------------------------------------------------
11/30/05  Common Stock  1,250,000  $50,000 for 1,250,000
          Warrant          62,500  shares of common stock and   Business Associate
                                   warrant for 62,500 shares
----------------------------------------------------------------------------------
12/2/05   Common Stock    625,000  $25,000 for 625,000 shares
          Warrant          31,250  of common stock and a        Business Associate
                                   warrant for 31,250 shares
----------------------------------------------------------------------------------
12/2/05   Common Stock    625,000  $25,000 for 625,000 shares
          Warrant          31,250  of common stock and a        Business Associate
                                   warrant for 31,250 shares
----------------------------------------------------------------------------------
12/2/05   Common Stock    625,000  $25,000 for 625,000 shares
          Warrant          31,250  of common stock and a        Business Associate
                                   warrant for 31,250 shares
----------------------------------------------------------------------------------
12/6/05   Common Stock  1,875,000  $75,000 for 1,875,000
          Warrant          93,750  shares of common stock and
                                   a warrant for 93,750         Business Associate
                                   shares
----------------------------------------------------------------------------------
12/6/05   Common Stock  1,875,000  $75,000 for 1,875,000
          Warrant          93,750  shares of common stock and
                                   a warrant for 93,750         Business Associate
                                   shares
----------------------------------------------------------------------------------
12/7/05   Common Stock    625,000  $25,000 for 625,000 shares
          Warrant          31,250  of common stock and a        Business Associate
                                   warrant for 31,250 shares
----------------------------------------------------------------------------------
12/7/05   Common Stock    250,000  $10,000 for 250,000 shares
          Warrant          12,500  of common stock and a        Business Associate
                                   warrant for 12,500 shares
----------------------------------------------------------------------------------
12/12/05  Common Stock    200,000  $8,000 for 200,000 shares
          Warrant          10,000  of common stock and a        Business Associate
                                   warrant for 10,000 shares
----------------------------------------------------------------------------------
12/20/05  Common Stock    375,000  $15,000 for 375,000 shares
          Warrant          18,750  of common stock and a        Business Associate
                                   warrant for 18,750 shares
----------------------------------------------------------------------------------
12/22/05  Common Stock    125,000  $5,000 for 125,000 shares
          Warrant           6,250  of common stock and a        Business Associate
                                   warrant for 6,250 shares
----------------------------------------------------------------------------------
12/22/05  Common Stock    937,500  $37,500 for 937,500 shares
          Warrant          46,875  of common stock and a        Business Associate
                                   warrant for 46,875 shares
----------------------------------------------------------------------------------
12/22/05  Common Stock    250,000  $10,000 for 250,000 shares
          Warrant          12,500  of common stock and a        Business Associate
                                   warrant for 12,500 shares
----------------------------------------------------------------------------------
</TABLE>

The warrants have an exercise price of $1.00 per share and a term of 3 years.


                                       6
<PAGE>
Exemption From Registration Claimed

     All of the sales by the Company of its unregistered securities were made by
the  Company  in  reliance  upon  Section 4(2) of the Securities Act of 1933, as
amended  (the  "1933 Act").  All of the individuals and/or entities listed above
that  purchased  the  unregistered  securities  were  almost  all  existing
shareholders,  all known to the Company and its management, through pre-existing
business  relationships,  as  long  standing  business  associates, friends, and
employees.  All  purchasers  were  provided  access to all material information,
which  they  requested, and all information necessary to verify such information
and  were  afforded access to management of the Company in connection with their
purchases.  All  purchasers  of  the  unregistered  securities  acquired  such
securities for investment and not with a view toward distribution, acknowledging
such  intent  to  the  Company. All certificates or agreements representing such
securities  that  were issued contained restrictive legends, prohibiting further
transfer of the certificates or agreements representing such securities, without
such  securities  either  being  first  registered  or  otherwise  exempt  from
registration  in  any  further  resale  or  disposition.


                                       7
<PAGE>
ITEM 6.   EXHIBITS

     (a)  EXHIBITS.  The  following  is  a  complete  list  of exhibits filed as
          part of this Form 10-QSB. Exhibit numbers correspond to the numbers in
          the Exhibit Table of Item 601 of Regulation S-B.

          Exhibit 11    Computation of Net Loss Per Share

          Exhibit 31.1  Certification  of  Chief  Executive  Officer pursuant to
                        Section 302 of the Sarbanes-Oxley Act

          Exhibit 31.2  Certification  of  Chief  Financial  Officer pursuant to
                        Section 302 of the Sarbanes-Oxley Act

          Exhibit 32.1  Certification  of  Principal  Executive  Officer
                        pursuant to Section 906 of the Sarbanes-Oxley Act

          Exhibit 32.2  Certification  of  Principal  Financial  Officer
                        pursuant to Section 906 of the Sarbanes-Oxley Act
                                        5
     (b)  CURRENT  REPORTS  ON  FORM  8-K.  The  registrant  filed the following
          current  reports  on  Form  8-K  during the quarter ended December 31,
          2005:

          -    Current  Report  on  Form  8-K  dated,  October  7,  2005,  filed
               with  the  Securities  and Exchange Commission on October 7, 2005
               (Item 7.01 Regulation FD Disclosure - Shareholder Letter and Item
               9.01  Financial Statements and Exhibits - copy of October 7, 2005
               Shareholder Letter)


                                       8
<PAGE>
                                   SIGNATURES

     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned,  thereunto  duly  authorized.

                                         VYTA  CORP

                                         (REGISTRANT)

Date:  February  21,  2006               /s/Paul  H.  Metzinger
                                         ------------------------------
                                         Paul  H.  Metzinger,
                                         President  &  CEO


Date:  February 21, 2006                 /s/Kristi J. Kampmann
                                         ------------------------------
                                         Kristi  J.  Kampmann,
                                         Chief  Financial  Officer


                                       9